b.next Establishes Synthetic Cell Manufacturing Plant and Ships 100th Cytosol Kit

Establishing a Synthetic Cell Supply Chain

b.next, initially founded to improve interoperability in synthetic cell research, has expanded its operations to include manufacturing. The company now operates a plant dedicated to producing "Cytosol," which are essential materials for constructing synthetic cells. This manufacturing capability is based on open specifications developed by Nucleus.

Addressing Infrastructure Gaps

The establishment of this industrial-grade infrastructure was an unexpected but necessary step for b.next. The company identified a lack of a dedicated physical supply chain as a significant barrier to the growth of synthetic cell technology, which previously relied heavily on academic efforts. The recent shipment of their 100th Cytosol kit marks a milestone in this endeavor.

Overcoming Licensing and Availability Challenges

b.next encountered significant hurdles in acquiring necessary components for synthetic cell engineering, specifically the 36 plasmids required for the OnePot PURE system. These plasmids were subject to restrictive material licensing terms (UBMTA), making them inaccessible to the company. Additionally, existing PURE plasmid sets were found to be incomplete or mutated, with only a few labs successfully building the system after extended periods.

Developing Open-Access Solutions

In response to these challenges, b.next redesigned and synthesized its own improved, open-access set of PURE plasmids. This initiative aims to provide the synthetic cell community with accessible and modifiable components, contrasting with previously available commercial formulations that lacked extensibility.